Related Experiment Video

Updated: May 24, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Interaction of Berberine derivative with protein POT1 affect telomere function in cancer cells

Nannan Xiao1, Siqi Chen, Yan Ma

  • 1School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou University City, PR China.

Biochemical and Biophysical Research Communications
|February 29, 2012
PubMed

Insights

Researchers identified Sysu-00692 as the first POT1-binding ligand, a crucial protein for telomere protection. This compound shows potential for developing new cancer treatments by interfering with POT1-telomeric DNA interactions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Protection of telomeres by the POT1 protein is vital for preventing cell aging and promoting immortality.
  • POT1 is recognized as a significant drug target for developing novel cancer therapies.

Purpose of the Study:

  • To clone, express, and purify recombinant human POT1.
  • To identify and characterize small molecules that bind to POT1.
  • To evaluate the potential of identified compounds as anticancer agents.

Main Methods:

  • Recombinant human POT1 expression and purification.
  • Protein activity validation using filter binding assays, FRET, and CD spectroscopy.
  • Ligand screening via Surface Plasmon Resonance (SPR) and Electrophoretic Mobility Shift Assay (EMSA).
  • In vivo assessment of compound effects on POT1-telomeric DNA binding using chromatin immunoprecipitation.

Main Results:

  • Recombinant human POT1 was successfully expressed, purified, and confirmed to be active.
  • Compound Sysu-00692 was identified as the first POT1-binding ligand.
  • Sysu-00692 demonstrated in vivo interference with POT1-telomeric DNA binding.
  • The compound exhibited mild inhibition of telomerase activity and cell proliferation.

Conclusions:

  • Compound Sysu-00692 represents a novel POT1-binding ligand with potential as a lead compound for cancer drug development.
  • This discovery provides a new avenue for designing anticancer drugs targeting the POT1 pathway.

More Related Videos

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Related Concept Videos

Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...